Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage

Stopped B2341002 was terminated on 26-OCT-2017 for strategic reasons. The decision to terminate the trial was not based on any safety concerns.

Conditions

• Intracerebral Hemorrhage

Interventions

• BIOLOGICAL: PF-05230907

Sponsor

Pfizer